With the rising incidence of cancer, chemotherapy has become a widely used treatment approach. However, the use of anticancer drugs such as doxorubicin (DOX) poses significant long-term risks due to its nonspecific distribution and severe side effects. Therefore, developing a nanoparticle-based drug delivery system (DDS) that enhances the bioavailability of DOX specifically to cancer cells is crucial while minimizing its side effects on normal cells.
View Article and Find Full Text PDF